Cargando…

The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial

INTRODUCTION: Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet...

Descripción completa

Detalles Bibliográficos
Autores principales: Soare, Andreea, Del Toro, Rossella, Roncella, Elena, Khazrai, Yeganeh Manon, Angeletti, Silvia, Dugo, Laura, Fallucca, Sara, Fontana, Lucia, Altomare, Maria, Formisano, Valeria, Capata, Francesca, Gesuita, Rosaria, Manfrini, Silvia, Fallucca, Francesco, Pianesi, Mario, Pozzilli, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379741/
https://www.ncbi.nlm.nih.gov/pubmed/25852946
http://dx.doi.org/10.1136/bmjdrc-2014-000079
_version_ 1782364241814093824
author Soare, Andreea
Del Toro, Rossella
Roncella, Elena
Khazrai, Yeganeh Manon
Angeletti, Silvia
Dugo, Laura
Fallucca, Sara
Fontana, Lucia
Altomare, Maria
Formisano, Valeria
Capata, Francesca
Gesuita, Rosaria
Manfrini, Silvia
Fallucca, Francesco
Pianesi, Mario
Pozzilli, Paolo
author_facet Soare, Andreea
Del Toro, Rossella
Roncella, Elena
Khazrai, Yeganeh Manon
Angeletti, Silvia
Dugo, Laura
Fallucca, Sara
Fontana, Lucia
Altomare, Maria
Formisano, Valeria
Capata, Francesca
Gesuita, Rosaria
Manfrini, Silvia
Fallucca, Francesco
Pianesi, Mario
Pozzilli, Paolo
author_sort Soare, Andreea
collection PubMed
description INTRODUCTION: Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D. METHODS: This was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed. RESULTS: After 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001). CONCLUSIONS: Findings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D. TRIAL REGISTRATION NUMBER: Current Controlled Trials ISRCTN10467793.
format Online
Article
Text
id pubmed-4379741
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43797412015-04-07 The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial Soare, Andreea Del Toro, Rossella Roncella, Elena Khazrai, Yeganeh Manon Angeletti, Silvia Dugo, Laura Fallucca, Sara Fontana, Lucia Altomare, Maria Formisano, Valeria Capata, Francesca Gesuita, Rosaria Manfrini, Silvia Fallucca, Francesco Pianesi, Mario Pozzilli, Paolo BMJ Open Diabetes Res Care Perspectives in Diabetes INTRODUCTION: Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D. METHODS: This was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed. RESULTS: After 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001). CONCLUSIONS: Findings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D. TRIAL REGISTRATION NUMBER: Current Controlled Trials ISRCTN10467793. BMJ Publishing Group 2015-03-26 /pmc/articles/PMC4379741/ /pubmed/25852946 http://dx.doi.org/10.1136/bmjdrc-2014-000079 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Perspectives in Diabetes
Soare, Andreea
Del Toro, Rossella
Roncella, Elena
Khazrai, Yeganeh Manon
Angeletti, Silvia
Dugo, Laura
Fallucca, Sara
Fontana, Lucia
Altomare, Maria
Formisano, Valeria
Capata, Francesca
Gesuita, Rosaria
Manfrini, Silvia
Fallucca, Francesco
Pianesi, Mario
Pozzilli, Paolo
The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
title The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
title_full The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
title_fullStr The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
title_full_unstemmed The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
title_short The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
title_sort effect of macrobiotic ma-pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the madiab trial
topic Perspectives in Diabetes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379741/
https://www.ncbi.nlm.nih.gov/pubmed/25852946
http://dx.doi.org/10.1136/bmjdrc-2014-000079
work_keys_str_mv AT soareandreea theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT deltororossella theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT roncellaelena theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT khazraiyeganehmanon theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT angelettisilvia theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT dugolaura theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT falluccasara theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT fontanalucia theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT altomaremaria theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT formisanovaleria theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT capatafrancesca theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT gesuitarosaria theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT manfrinisilvia theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT falluccafrancesco theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT pianesimario theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT pozzillipaolo theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT soareandreea effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT deltororossella effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT roncellaelena effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT khazraiyeganehmanon effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT angelettisilvia effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT dugolaura effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT falluccasara effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT fontanalucia effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT altomaremaria effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT formisanovaleria effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT capatafrancesca effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT gesuitarosaria effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT manfrinisilvia effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT falluccafrancesco effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT pianesimario effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial
AT pozzillipaolo effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial